Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CYP3A4 antisense RNA 1 (CYP3A4-AS1; AC069294.1) is a long noncoding RNA located within the CYP3A4 gene locus and transcribed from the antisense strand[1][4]. It acts as a negative regulator of the cytochrome P450 enzymes CYP3A4 and CYP3A5, two major enzymes involved in hepatic drug metabolism. Its expression is inversely correlated with CYP3A4 and CYP3A5 mRNA levels, and it is upregulated by specific genetic variants such as the CYP3A4*1G allele. This upregulation leads to decreased expression of CYP3A4 and CYP3A5, affecting inter-individual variability in drug metabolism and potentially influencing clinical drug responses[1][4]. CYP3A4-AS1 does not itself directly interact with drugs, but it modulates the metabolic capacity of the liver by altering CYP3A4 and CYP3A5 levels. The regulatory mechanism does not appear to extend efficiently to other CYP3A family members (such as CYP3A7 and CYP3A43) under normal physiological conditions[1].
negative regulation of CYP3A4 and CYP3A5 expression levels through antisense-mediated transcriptional effects
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CYP3A4 antisense RNA 1 (CYP3A4-AS1).